TableĀ 2

Histological features of olmesartan and other ARB users compared with controls

Olmesartan analysisOther ARB analysis
Olmesartan users (n=20) (%)Matched controls (n=20) (%)p ValueOther ARB users (n=20) (%)Matched controls (n=20) (%)p Value
Villous atrophy4/16 (25)*1/16 (6)0.331/14 (7)*2/19 (11)1.0
Crypt hyperplasia4/16 (25)*2/17 (12)0.403/14 (21)*4/18 (22)1.0
Mean maximum IEL count13.710.60.0913.018.50.35
Generalised IEL increase4/20 (20)2/20 (10)0.672/20 (10)6/20 (30)0.24
Chronic inflammation5/20 (25)2/20 (10)0.407/20 (35)6/20 (30)1.0
Eosinophilia2/20 (10)0/20 (0)0.493/20 (15)2/20 (10)1.0
Neutrophilia8/20 (40)6/20 (30)0.744/20 (20)7/20 (35)0.48
Increased crypt apoptosis5/20(25)2/20 (10)0.406/20 (30)8/20 (40)0.74
One or more sprue-like features (architectural abnormalities, generalised increased IEL, chronic inflammation)10/20 (50)4/20 (20)0.109/20 (45)12/20 (60)0.34
  • *Villous atrophy and crypt hyperplasia was not evaluated in 4 olmesartan cases and in 6 ARB cases due to poor orientation.

  • ARB, angiotensin receptor blocker; IEL, intraepithelial lymphocyte.